Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
Total Valuation
Bicycle Therapeutics has a market cap or net worth of $597.91M. The enterprise value is $13.93M.
Market Cap$597.91M
Enterprise Value$13.93M
Share Statistics
Bicycle Therapeutics has 47,761,845 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47,761,845
Owned by Insiders23.78%
Owned by Institutions64.75%
Financial Efficiency
Bicycle Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -22.94%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-22.94%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee115.66K
Profits Per Employee-554.20K
Employee Count305
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicycle Therapeutics is -48.21. Bicycle Therapeutics’s PEG ratio is -0.18.
PE Ratio-48.21
PS Ratio0.00
PB Ratio3.24
Price to Fair Value10.28
Price to FCF-8.35
Price to Operating Cash Flow-10.20
PEG Ratio-0.18
Income Statement
In the last 12 months, Bicycle Therapeutics had revenue of 35.27M and earned -169.03M in profits. Earnings per share was -0.29.
Revenue35.27M
Gross Profit28.11M
Operating Income-209.87M
Pretax Income-173.80M
Net Income-169.03M
EBITDA-164.89M
Earnings Per Share (EPS)-0.29
Cash Flow
In the last 12 months, operating cash flow was -180.23M and capital expenditures -1.83M, giving a free cash flow of -182.13M billion.
Operating Cash Flow-180.23M
Free Cash Flow-182.13M
Free Cash Flow per Share-3.81
Dividends & Yields
Bicycle Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change-63.95%
50-Day Moving Average8.06
200-Day Moving Average15.48
Relative Strength Index (RSI)56.25
Average Volume (3m)294.61K
Important Dates
Bicycle Therapeutics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Bicycle Therapeutics as a current ratio of 13.81, with Debt / Equity ratio of 16.37%
Current Ratio13.81
Quick Ratio13.81
Debt to Market Cap0.00
Net Debt to EBITDA5.28
Interest Coverage Ratio-121.31
Taxes
In the past 12 months, Bicycle Therapeutics has paid -4.76M in taxes.
Income Tax-4.76M
Effective Tax Rate0.03
Enterprise Valuation
Bicycle Therapeutics EV to EBITDA ratio is -44.14, with an EV/FCF ratio of -43.86.
EV to Sales206.35
EV to EBITDA-44.14
EV to Free Cash Flow-43.86
EV to Operating Cash Flow-44.19
Balance Sheet
Bicycle Therapeutics has $792.97M in cash and marketable securities with $8.32M in debt, giving a net cash position of -$784.65M billion.
Cash & Marketable Securities$792.97M
Total Debt$8.32M
Net Cash-$784.65M
Net Cash Per Share-$16.43
Tangible Book Value Per Share$1.36
Margins
Gross margin is 74.51%, with operating margin of -594.96%, and net profit margin of -479.18%.
Gross Margin74.51%
Operating Margin-594.96%
Pretax Margin-492.69%
Net Profit Margin-479.18%
EBITDA Margin-467.45%
EBIT Margin-487.78%
Analyst Forecast
The average price target for Bicycle Therapeutics is $23.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.14
Price Target Upside164.16% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast-38.14%
EPS Growth Forecast29.69%